Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $13.58 a share, with a consensus analyst price target of $23.00 and a 52-week trading range of $7.67 to $18.00.
Endocyte Inc. (NASDAQ: ECYT) will present data in regards to its PSMA-617 at the Society of Nuclear Medicine and Molecular Imaging annual meeting on June 23 to 26. PSMA-617 is a radioligand therapy for the targeted treatment of prostate cancer. Shares of Endocyte were last seen at $13.79 on Friday, with a consensus price target of $17.67 and a 52-week range of $1.17 to $15.45.
Achaogen Inc. (NASDAQ: AKAO) has a Prescription Drug User Fee Act (PDUFA) date scheduled for June 25 for its lead product, plazomicin, which is being developed to treat serious bacterial infections. Achaogen shares traded at $12.42, with a consensus price target of $18.20 and a 52-week range of $9.83 to $25.22.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is readying for its commercial launch of Palynziq (pegvaliase) in the United States, for the treatment of phenylketonuria. Shares of BioMarin were trading at $99.03, with a consensus analyst target of $114.14 and a 52-week range of $75.81 to $99.76.
Global Blood Therapeutics Inc. (NASDAQ: GBT) is expected to announce Part A (dose finding for Part B) of its Phase 3 HOPE trial for people with sickle cell disease later this month. Shares of GBT were last seen at $42.05 on Friday, with a consensus price target of $72.46 and a 52-week range of $24.02 to $68.05.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.78, with a consensus analyst target of $80.17 and a 52-week range of $22.25 to $76.29.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
